Brokerages Anticipate Abeona Therapeutics Inc (ABEO) Will Announce Earnings of -$0.16 Per Share

Analysts predict that Abeona Therapeutics Inc (NASDAQ:ABEO) will post earnings of ($0.16) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Abeona Therapeutics’ earnings, with estimates ranging from ($0.20) to ($0.05). Abeona Therapeutics posted earnings of ($0.21) per share during the same quarter last year, which would suggest a positive year over year growth rate of 23.8%. The firm is expected to report its next quarterly earnings results on Tuesday, August 21st.

On average, analysts expect that Abeona Therapeutics will report full-year earnings of ($0.70) per share for the current financial year, with EPS estimates ranging from ($0.89) to ($0.34). For the next financial year, analysts forecast that the company will report earnings of ($0.64) per share, with EPS estimates ranging from ($0.98) to ($0.29). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.01. The company had revenue of $2.60 million during the quarter, compared to the consensus estimate of $0.27 million. Abeona Therapeutics had a negative net margin of 939.83% and a negative return on equity of 23.57%.

ABEO has been the subject of several recent research reports. HC Wainwright set a $30.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 2nd. Maxim Group set a $35.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 19th. Cantor Fitzgerald set a $36.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, March 20th. ValuEngine raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Finally, Zacks Investment Research downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 21st. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $28.56.

Shares of NASDAQ:ABEO traded down $0.20 during midday trading on Friday, hitting $15.90. 850,422 shares of the company’s stock were exchanged, compared to its average volume of 1,082,414. The company has a market cap of $749.79 million, a PE ratio of -23.94 and a beta of 1.27. Abeona Therapeutics has a 12 month low of $4.55 and a 12 month high of $22.75.

A number of hedge funds have recently modified their holdings of ABEO. Knott David M bought a new stake in Abeona Therapeutics in the 1st quarter worth about $101,000. Virginia Retirement Systems ET AL bought a new stake in Abeona Therapeutics in the 1st quarter worth about $152,000. Teacher Retirement System of Texas bought a new stake in Abeona Therapeutics in the 4th quarter worth about $163,000. Sabby Management LLC bought a new stake in Abeona Therapeutics in the 1st quarter worth about $187,000. Finally, MetLife Investment Advisors LLC bought a new stake in Abeona Therapeutics in the 4th quarter worth about $194,000. 69.11% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply